Form 13-F position report

ALX ONCOLOGY HLDGS INC

Reported by STATE STREET CORPORATION

ALXO CUSIP 00166B105 Manager CIK 0000093751

Reported 384,563 shares, up 28,758 (8.1%) from the prior quarter.

Reported value 27.9%; share count 8.1% vs. the prior quarter.

Added
% of reported 13F value < 0.01% This manager · Q3 2022
Shares 384,563 Quarter-end amount reported
Reported value $3,680,000 Fair value at quarter end
Consecutive quarters held 9 Through Q3 2022

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-09-30 63634000
2021-12-31 30996000
2022-03-31 36060000
2022-06-30 2878000
2022-09-30 3680000
2022-12-31 4435309
2023-03-31 1780627
2023-06-30 2864457
2023-09-30 1868923
2023-12-31 7467275
2024-03-31 6175617
2024-06-30 4254448
2024-09-30 1221904
2024-12-31 1142485
2025-03-31 447845
2025-06-30 51569
2025-09-30 204828
2025-12-31 140378
2026-03-31 352535
2026-06-30 3102733

Quarterly position history

How this manager's reported quarter-end position changed over time.

20 quarters
Quarterly reported position history for ALX ONCOLOGY HLDGS INC held by STATE STREET CORPORATION.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q2 2026 Added 1,498,905 +1,323,077 (752.5%) < 0.01% $3,102,733 2026-08-07
Q1 2026 Added 175,828 +51,600 (41.5%) < 0.01% $352,535 2026-05-15
Q4 2025 Added 124,228 +12,300 (11.0%) < 0.01% $140,378 2026-02-13
Q3 2025 Reduced 111,928 -12,304 (-9.9%) < 0.01% $204,828 2025-11-14
Q2 2025 Reduced 124,232 -594,621 (-82.7%) < 0.01% $51,569 2025-08-14
Q1 2025 Added 718,853 +34,730 (5.1%) < 0.01% $447,845 2025-05-15
Q4 2024 Added 684,123 +12,747 (1.9%) < 0.01% $1,142,485 2025-02-14
Q3 2024 Reduced 671,376 -34,171 (-4.8%) < 0.01% $1,221,904 2024-11-14
Q2 2024 Added 705,547 +151,680 (27.4%) < 0.01% $4,254,448 2024-08-14
Q1 2024 Added 553,867 +52,371 (10.4%) < 0.01% $6,175,617 2024-05-15
Q4 2023 Added 501,496 +112,137 (28.8%) < 0.01% $7,467,275 2024-02-14
Q3 2023 Added 389,359 +7,940 (2.1%) < 0.01% $1,868,923 2023-11-14
Q2 2023 Reduced 381,419 -12,525 (-3.2%) < 0.01% $2,864,457 2023-08-14
Q1 2023 Added 393,944 +394 (0.1%) < 0.01% $1,780,627 2023-05-15
Q4 2022 Added 393,550 +8,987 (2.3%) < 0.01% $4,435,309 2023-02-14
Q3 2022 Added 384,563 +28,758 (8.1%) < 0.01% $3,680,000 2022-11-15
Q2 2022 Reduced 355,805 -1,777,939 (-83.3%) < 0.01% $2,878,000 2022-08-15
Q1 2022 Added 2,133,744 +691,410 (47.9%) < 0.01% $36,060,000 2022-05-16
Q4 2021 Added 1,442,334 +580,779 (67.4%) < 0.01% $30,996,000 2022-02-14
Q3 2021 Reduced 861,555 -193,322 (-18.3%) < 0.01% $63,634,000 2021-11-15
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

110 managers reported ALX ONCOLOGY HLDGS INC for Q3 2022.

Managers reporting ALX ONCOLOGY HLDGS INC in Q3 2022.
Manager Activity Shares Change % of reported 13F Reported value Tenure
venBio Partners LLC Unchanged 9,699,925 0 21.48% $92,828,000 9 qtrs
FMR LLC Added 4,630,574 +644,360 < 0.01% $44,315,000 9 qtrs
Vivo Capital LLC Unchanged 4,220,048 0 4.46% $40,386,000 9 qtrs
Logos Global Management LP Reduced 2,971,352 -165,000 3.5% $28,436,000 9 qtrs
ORBIMED ADVISORS LLC Added 2,871,000 +684,731 0.52% $27,475,000 8 qtrs
BlackRock Inc Added 1,670,402 +8,120 < 0.01% $15,987,000 9 qtrs
VANGUARD GROUP INC Added 1,411,009 +86,272 < 0.01% $13,503,000 9 qtrs
EVENTIDE ASSET MANAGEMENT LLC New 902,000 +902,000 0.17% $8,632,000 1 qtr
Redmile Group LLC Reduced 752,097 -14,700 0.28% $7,198,000 9 qtrs
Cormorant Asset Management LP Unchanged 712,079 0 0.48% $6,815,000 9 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2022
Filed
November 15, 2022
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
347,347
Shared
0
None
37,216

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.